SPY — SPDR S&P 500 ETF
Is SPY overbought or oversold? Here is the current MarketMoodz read.
SPDR S&P 500 ETF (SPY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The ETF name (Index Fund) last closed at $739.96. The rating moved from Neutral to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$739.96
- Last changeMoved from Neutral to Oversold on November 14, 2026
- SectorETF
- IndustryIndex Fund
AI analysis
SPDR S&P 500 ETF (SPY) offers diversified, highly liquid exposure to large-cap U.S. equities and stands to benefit from the current earnings-driven risk-on tone. The ETF's low cost and tight tracking make it an efficient vehicle to capture modest upside if earnings continue to surprise positively, while concentrated mega-cap weights provide both catalyst-driven upside and the risk of volatility if a few names stumble. Near-term performance will be sensitive to aggregate earnings outcomes, Fed messaging on rates, and any sudden geopolitical or macro shocks.
Key factors
- Broad market exposure to S&P 500 provides diversified, liquid access to large-cap U.S. equities
- High liquidity and low expense ratio make SPY cost-efficient for tactical and strategic allocations
- Current market tone shows risk-on positioning driven by earnings momentum and no major policy shocks
- Concentration in mega-cap growth names; beneficiary of flows into growth sectors amid steady rates
- Strong short-term catalysts from upcoming corporate earnings that could lift index performance
Risks
- Disappointing aggregate earnings or guidance from large S&P 500 constituents could trigger sharp declines
- Renewed rate-hike expectations or unexpected Fed communication could reduce equity multiples
- Geopolitical events or systemic shocks could reverse risk-on sentiment rapidly
- Market breadth deterioration: narrow rally led by a handful of mega-caps could leave SPY vulnerable
- Tracking error or temporary liquidity dislocations in stressed markets (though historically low for SPY)
Latest MarketMoodz coverage
- Independent Pharmacies Sue Prime Therapeutics Over Price-Fixing2026-07-08
- Immunome’s Varegacestat Enters FDA Review After Strong Phase 3 Signals2026-07-08
- Sino Biopharma Accelerates Growth With GSK, AstraZeneca Deals2026-07-08
- EU Upholds DMA Ruling Against Apple, Threat to App Store Revenue2026-07-08
- NY Fed Study Reframes Bank Runs: Fundamentals, Not Runs, Matter2026-07-08
See today's live rating, score and targets
Members see the live hourly rating for SPY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.